Hermes Biosciences closed a $6 million seed round led by Genoa Ventures to commercialize a benchtop, hands‑off extracellular vesicle (EV) isolation system aimed at research and clinical labs. The San Francisco startup says the platform will make EV workflows reproducible and clinically accessible, addressing sensitivity gaps that limit ctDNA and protein analytes in early diagnostics. Hermes framed EVs as rich biomarkers for disease detection and said the funding will support product development and a commercial launch next year. The round signals investor appetite for enabling technologies that unlock new analytes for precision diagnostics.